SpliceBio
Last verified 2026-04-29. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $135.0Mattributed |
|---|---|
| Latest round | series-b, $135.0M, 2025-06-01attributed |
| Founded | unknown |
| Headquarters | Barcelona |
| Industry | bio |
| Stage | series-b+ |
| Website | splice.bio |
SpliceBio is a clinical-stage genetic medicines company using Protein Splicing to treat diseases caused by mutations in genes too large for a standard AAV vector. It develops therapies for inherited retinal and neurological disorders, led by SB-007 for Stargardt disease. Its platform splits and reassembles large proteins so AAV can deliver them.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-06-01 | series-b | $135.0M | undisclosed |
Detected tech stack
Cloudflare, WordPress 7.0, MonsterInsights 10.1.3, Yoast SEO 27.6, Google Analytics, Google Tag Manager, jQuery Migrate 3.4.1, imagesLoaded 4.1.4, PHP, DoubleClick Floodlight, Contact Form 7 6.1.6, CookieYes
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series B, $135.0M | attributed | sifted named as publisher. No document URL on file. |
| Total raised $135.0M | attributed | sifted named as publisher. No document URL on file. |
| Company existence | self-reported | splice.bio, read 2026-04-29 |
| Description | self-reported | splice.bio, read 2026-04-29 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.